Feromics has demonstrated the effectiveness of in-droplet live cell immunoassays for accurately profiling patients' immune cells. Building on this foundation, the company is advancing its proprietary Patient Immune Profiling (PIP) platform, paired with advanced imaging and powerful AI tools, to develop and validate a cutting-edge IVD point-of-care device. This technology will support clinicians in predicting patient responses to immunotherapy and provide critical insights into immune cell diversity, driving personalized medicine forward and improving immunotherapy outcomes.